PYC Therapeutics (ASX:PYC) lodged its Appendix 4E Preliminary Financial Report for the year ended 30 June 2026 on 28 August 2026. The report showed income from ordinary activities of $39,677,397, up 51.6%, and a loss after tax attributable to owners of $43,341,565, which was 13.8% lower than the previous period. The announcement was dated in Perth, Australia and San Francisco, California.

WHAT PYC THERAPEUTICS DOES

PYC Therapeutics is a clinical-stage biotechnology company creating a new generation of RNA therapies intended for patients with genetic diseases. The company states that it uses a proprietary drug delivery platform to enhance the potency of precision medicines within the RNA therapeutic class, which it describes as rapidly growing and commercially proven.

PYC's Drug Development programs target monogenic diseases, which are conditions caused by a change in a single gene. The company cites research based on exome sequencing of the UK Biobank to describe monogenic diseases as the indications with the highest likelihood of success in clinical development. The company operates from Perth and San Francisco, and the announcement notes that Dr Rohan Hockings is Executive Director and Chief Executive Officer for Perth.

RESULTS FOR ANNOUNCEMENT TO THE MARKET

Appendix 4E is a preliminary final report that listed entities lodge with the ASX when they report full year results. PYC's report lists the reporting period as the year ended 30 June 2026 and the previous period as the year ended 30 June 2025.

Under the heading of results for announcement to the market, income from ordinary activities was $39,677,397, up 51.6%. The loss from ordinary activities after tax attributable to the owners of PYC Therapeutics Limited and its controlled entities was $43,341,565, down 13.8%. The loss for the year attributable to owners was reported at the same amount.

The company stated that for commentary on the results of the Group, readers should refer to the FY2026 Annual Report. The Appendix 4E itself does not provide a narrative explanation of the movements in income or loss.

NET TANGIBLE ASSETS, CONTROLLED ENTITIES AND AUDIT STATUS

Net tangible assets per ordinary security were 70.13 cents for the reporting period, compared with 28.56 cents in the previous period. The report notes that the comparative figure has been calculated using post-consolidation ordinary securities, meaning it reflects the share count after a consolidation of the company's shares.

On control of entities, the report states that PYC Therapeutics Limited maintained its Equity share in Vision Pharma Limited during the period ending 30 June 2026, holding its ownership stake at 97.1%.

PYC reported that no dividends were paid, recommended or declared in either the current or previous financial period. The Dividend reinvestment plan, associates and joint venture sections of the report are marked as not applicable.

The report states that the financial statements were prepared in accordance with Australian Accounting Standards as issued by the Australian Accounting Standards Board, the Corporations Act 2001 and other mandatory professional reporting requirements. It also states that the financial statements have been audited by the Group's independent auditor, who issued an unqualified audit report. The document was signed by Dr Hockings on 28 August 2026, and the announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.

RISKS AND WHAT TO WATCH

PYC describes itself as clinical-stage, and the report shows a loss after tax of $43,341,565 for the year. The Appendix 4E does not include a cash flow statement, Balance Sheet detail or an outlook, and refers readers to the FY2026 Annual Report for commentary. Information on research progress, clinical trial timing, funding and expenditure is therefore not covered in this document.

The net tangible assets figure of 70.13 cents per security is compared with a prior period figure that has been restated for share consolidation. The company reported no dividends for either period. Readers assessing the company's position would need to refer to the full annual report, which contains the detailed financial statements and notes referred to in the Appendix 4E.

NEXT MILESTONES

The Appendix 4E directs readers to the FY2026 Annual Report for commentary on the results of the Group. Additional information may be published through further ASX announcements, and the company provides an Investor relations and media contact at [email protected]. The report does not include dates for clinical, regulatory or Capital Markets events.